Literature DB >> 29253116

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

A R Sánchez-Paulete, A Teijeira, F J Cueto, S Garasa, J L Pérez-Gracia, A Sánchez-Arráez, D Sancho, I Melero.   

Abstract

Entities:  

Year:  2017        PMID： 29253116     DOI： 10.1093/annonc/mdx727

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  22 in total

1.  Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.

Authors:  Young-Hee Kim; Thi-Anh-Thuy Tran; Thi-Hoang-Oanh Duong; Shin Jung; In-Young Kim; Kyung-Sub Moon; Woo-Youl Jang; Hyun-Ju Lee; Je-Jung Lee; Tae-Young Jung
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

2.  Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.

Authors:  Jonas Rm Van Audenaerde; Elly Marcq; Bianca von Scheidt; Ashleigh S Davey; Amanda J Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y Slaney; Marc Peeters; Michael H Kershaw; Phillip K Darcy; Evelien Ljm Smits
Journal:  Clin Transl Immunology       Date:  2020-08-15

3.  TLR4, but Neither Dectin-1 nor Dectin-2, Participates in the Mollusk Hemocyanin-Induced Proinflammatory Effects in Antigen-Presenting Cells From Mammals.

Authors:  José M Jiménez; Michelle L Salazar; Sergio Arancibia; Javiera Villar; Fabián Salazar; Gordon D Brown; Ed C Lavelle; Luisa Martínez-Pomares; Jafet Ortiz-Quintero; Sergio Lavandero; Augusto Manubens; María Inés Becker
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

4.  Physical plasma-treated saline promotes an immunogenic phenotype in CT26 colon cancer cells in vitro and in vivo.

Authors:  Eric Freund; Kim Rouven Liedtke; Julia van der Linde; Hans-Robert Metelmann; Claus-Dieter Heidecke; Lars-Ivo Partecke; Sander Bekeschus
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 5.  Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy.

Authors:  Thiago A Patente; Mariana P Pinho; Aline A Oliveira; Gabriela C M Evangelista; Patrícia C Bergami-Santos; José A M Barbuto
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

Review 6.  Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.

Authors:  Lorenzo Castagnoli; Francesca De Santis; Tatiana Volpari; Claudio Vernieri; Elda Tagliabue; Massimo Di Nicola; Serenella M Pupa
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

Review 7.  Tumour neoantigen mimicry by microbial species in cancer immunotherapy.

Authors:  Maximilian Boesch; Florent Baty; Sacha I Rothschild; Michael Tamm; Markus Joerger; Martin Früh; Martin H Brutsche
Journal:  Br J Cancer       Date:  2021-04-06       Impact factor: 7.640

8.  Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine.

Authors:  María Pulido; Virginia Chamorro; Irene Romero; Ignacio Algarra; Alba S-Montalvo; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

9.  Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.

Authors:  Alex Karlsson-Parra; Juliana Kovacka; Emilia Heimann; Margareth Jorvid; Sijme Zeilemaker; Sharon Longhurst; Peter Suenaert
Journal:  Pharm Res       Date:  2018-06-14       Impact factor: 4.200

10.  Cellular cytotoxicity is a form of immunogenic cell death.

Authors:  Luna Minute; Alvaro Teijeira; Alfonso R Sanchez-Paulete; Maria C Ochoa; Maite Alvarez; Itziar Otano; Iñaki Etxeberrria; Elixabet Bolaños; Arantza Azpilikueta; Saray Garasa; Noelia Casares; Jose Luis Perez Gracia; Maria E Rodriguez-Ruiz; Pedro Berraondo; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.